Compare IIPR & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IIPR | AGIO |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | United States |
| Employees | 23 | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.2B |
| IPO Year | N/A | 2013 |
| Metric | IIPR | AGIO |
|---|---|---|
| Price | $63.53 | $40.11 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $45.00 | $38.88 |
| AVG Volume (30 Days) | 301.7K | ★ 1.2M |
| Earning Date | 05-04-2026 | 04-29-2026 |
| Dividend Yield | ★ 14.28% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,011,000.00 |
| Revenue This Year | $2.69 | $76.75 |
| Revenue Next Year | $3.80 | $170.73 |
| P/E Ratio | $10.92 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.58 | $22.24 |
| 52 Week High | $64.84 | $46.00 |
| Indicator | IIPR | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 60.66 | 64.07 |
| Support Level | $48.01 | $39.31 |
| Resistance Level | N/A | $43.81 |
| Average True Range (ATR) | 1.59 | 1.75 |
| MACD | 0.01 | 0.12 |
| Stochastic Oscillator | 71.81 | 54.62 |
Innovative Industrial Properties Inc is a real estate investment trust focused on the acquisition, ownership and management of specialized industrial and commercial properties in the United States. Its properties are prominently leased to state-licensed operators for their regulated cannabis facilities. The company conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by its Operating Partnership, directly or through subsidiaries. Its segments are: Cannabis Portfolio and Life Science Portfolio, with the majority of revenue coming from the Cannabis Portfolio segment, which involves acquiring, developing, and leasing real estate to regulated cannabis operators on long-term triple-net leases.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.